NYSE - Nasdaq Real Time Price USD
AbbVie Inc. (ABBV)
235.65 +0.89 (+0.38%)
As of 2:58:49 PM EDT. Market Open.
Trade AbbVie on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for ABBV
- Previous Close
234.76 - Open
236.35 - Bid 235.02 x 30000
- Ask 235.09 x 30000
- Day's Range
232.85 - 237.33 - 52 Week Range
181.73 - 244.81 - Volume
3,139,677 - Avg. Volume
6,161,837 - Market Cap (intraday)
416.336B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
115.51 - EPS (TTM)
2.04 - Earnings Date Jul 30, 2026
- Forward Dividend & Yield 6.92 (2.95%)
- Ex-Dividend Date Jul 15, 2026
- 1y Target Est
253.83
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ABBV
4.82%
S&P 500 (^GSPC)
7.31%
1-Year Return
ABBV
31.14%
S&P 500 (^GSPC)
20.58%
3-Year Return
ABBV
93.05%
S&P 500 (^GSPC)
68.93%
5-Year Return
ABBV
147.73%
S&P 500 (^GSPC)
72.17%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
414.77B
Enterprise Value
478.24B
Trailing P/E
115.08
Forward P/E
16.47
PEG Ratio (5yr expected)
0.65
Price/Sales (ttm)
6.63
Price/Book (mrq)
--
Enterprise Value/Revenue
7.61
Enterprise Value/EBITDA
28.26
Financial Highlights
Profitability and Income Statement
Profit Margin
5.79%
Return on Assets (ttm)
10.03%
Return on Equity (ttm)
--
Revenue (ttm)
62.82B
Net Income Avi to Common (ttm)
3.6B
Diluted EPS (ttm)
2.04
Balance Sheet and Cash Flow
Total Cash (mrq)
9.39B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
20.81B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreAbbVie: Apogee Acquisition Brings Significant Weight to Immunology Pipeline
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
RatingPrice TargetAbbVie: Apogee Acquisition Brings Significant Weight to Immunology Pipeline
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
RatingPrice TargetAbbVie Earnings: Shares Remain Fairly Valued; Immunology Portfolio and Pipeline Look Solid
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
RatingPrice TargetArgus Quick Note: Weekly Stock List for 05/18/2026: Focus List Changes
Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.